Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating restated by Stifel Nicolaus in a research report issued on Friday. They presently have a $65.00 price objective on the stock. Stifel Nicolaus’ target price suggests a potential upside of 2.91% from the company’s previous close.

ZTS has been the topic of a number of other reports. Hilliard Lyons assumed coverage on Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. Credit Suisse Group boosted their price objective on Zoetis from $61.00 to $67.00 and gave the company an “outperform” rating in a research report on Wednesday, May 24th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research report on Wednesday, May 10th. Cowen and Company set a $70.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Monday. Finally, BMO Capital Markets cut Zoetis from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $64.00 to $65.00 in a research report on Tuesday, June 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.47.

Shares of Zoetis (NYSE:ZTS) traded up 0.65% during trading on Friday, reaching $63.16. The company had a trading volume of 2,097,192 shares. The firm has a market capitalization of $31.00 billion, a PE ratio of 36.72 and a beta of 1.03. The stock has a 50 day moving average price of $62.65 and a 200 day moving average price of $57.14. Zoetis has a 12 month low of $46.86 and a 12 month high of $63.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 4th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.05. The business had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. Zoetis’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.48 earnings per share. On average, equities research analysts forecast that Zoetis will post $2.33 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/21/zoetis-inc-nysezts-receives-buy-rating-from-stifel-nicolaus.html.

In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of the business’s stock in a transaction on Friday, May 12th. The stock was sold at an average price of $60.16, for a total value of $348,025.60. Following the transaction, the insider now owns 24,415 shares of the company’s stock, valued at $1,468,806.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.31% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. DAVENPORT & Co LLC raised its position in Zoetis by 24.7% in the first quarter. DAVENPORT & Co LLC now owns 359,906 shares of the company’s stock worth $19,231,000 after buying an additional 71,360 shares in the last quarter. Ameriprise Financial Inc. raised its position in Zoetis by 21.1% in the first quarter. Ameriprise Financial Inc. now owns 1,614,416 shares of the company’s stock worth $86,167,000 after buying an additional 281,139 shares in the last quarter. Atalanta Sosnoff Capital LLC raised its position in Zoetis by 39.1% in the first quarter. Atalanta Sosnoff Capital LLC now owns 778,212 shares of the company’s stock worth $41,533,000 after buying an additional 218,905 shares in the last quarter. AXA raised its position in Zoetis by 0.8% in the first quarter. AXA now owns 242,831 shares of the company’s stock worth $12,960,000 after buying an additional 1,900 shares in the last quarter. Finally, Wealthfront Inc. raised its position in Zoetis by 14.8% in the fourth quarter. Wealthfront Inc. now owns 13,427 shares of the company’s stock worth $719,000 after buying an additional 1,731 shares in the last quarter. 95.10% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.